Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.

Cancer medicine - 1 May 2017

Hu Wenwei, Yang Yang, Zhang Longzhen, Yin Jianxin, Huang Jingwei, Huang Lei, Gu Hua, Jiang Gening, Fang Jianmin

Abstract excerpt

Cancer cells release DNA fragments into plasma as circulating free DNA (cfDNA). However, quantitative measurement of tumor-derived DNA in cfDNA remains challenge. The purpose of this study was to quantitatively assess tumor-derived DNA in lung cancer patients. By optimizing competitive allele-specific TaqMan PCR (CAST-PCR), we assessed the copy number of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to ErbB Receptors

Share to Gene Dosage

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 28382702
DOI: 10.1002/cam4.980
PMCID: PMC5430107

Genes

EGFR
CAST
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.PMID 28382702Read ↗

Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.Semantic proximity Read ↗

Circulating tumor DNA detection in lung cancer patients before and after surgery.Semantic proximity Read ↗

Dynamic changes of circulating tumour DNA in surgical lung cancer patients: protocol for a prospective observational study.Semantic proximity Read ↗

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung CancerSemantic proximity Read ↗

Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).Semantic proximity Read ↗

Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer.Semantic proximity Read ↗

Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal CancerSemantic proximity Read ↗

Circulating tumor DNA detection in peripheral blood in postoperative efficacy evaluation and recurrence risk prediction of lung cancer.Semantic proximity Read ↗

Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma EGFR Mutations.Semantic proximity Read ↗

Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients.Semantic proximity Read ↗

Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer.Semantic proximity Read ↗

Quantification of concentration and assessment of EGFR mutation in circulating DNA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.